In addition, we also examined the effects of atomoxetine (representative ADHD medicine), which exhibits dual norepinephrine transporter (NET) inhibition [44] and NMDA receptor antagonism [45]. Here, SLC6A2 is linked to attention deficit-hyperactivity disorder.